Lurbinectedin inactivates the Ewing sarcoma oncoprotein EWS-FLI1 by redistributing it within the nucleus

Matt L. Harlow, Nichole Maloney, Joseph Roland, Maria Jose Guillen Navarro, Matthew K. Easton, Susan M. Kitchen-Goosen, Elissa A. Boguslawski, Zachary B. Madaj, Ben K. Johnson, Megan J. Bowman, Maurizio D'Incalci, Mary E. Winn, Lisa Turner, Galen Hostetter, Carlos María Galmarini, Pablo M. Aviles, Patrick J. Grohar

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

There is a great need to develop novel approaches to target oncogenic transcription factors with small molecules. Ewing sarcoma is emblematic of this need, as it depends on the continued activity of the EWS-FLI1 transcription factor to maintain the malignant phenotype. We have previously shown that the small molecule trabectedin interferes with EWS-FLI1. Here, we report important mechanistic advances and a second-generation inhibitor to provide insight into the therapeutic targeting of EWS-FLI1. We discovered that trabectedin functionally inactivated EWS-FLI1 by redistributing the protein within the nucleus to the nucleolus. This effect was rooted in the wild-type functions of the EWSR1, compromising the N-terminal half of the chimeric oncoprotein, which is known to be similarly redistributed within the nucleus in the presence of UV light damage. A second-generation trabectedin analogue lurbinectedin (PM01183) caused the same nuclear redistribution of EWS-FLI1, leading to a loss of activity at the promoter, mRNA, and protein levels of expression. Tumor xenograft studies confirmed this effect, and it was increased in combination with irinotecan, leading to tumor regression and replacement of Ewing sarcoma cells with benign fat cells. The net result of combined lurbinectedin and irinotecan treatment was a complete reversal of EWS-FLI1 activity and elimination of established tumors in 30% to 70% of mice after only 11 days of therapy. Our results illustrate the preclinical safety and efficacy of a disease-specific therapy targeting the central oncogenic driver in Ewing sarcoma.

Original languageEnglish
Pages (from-to)6657-6668
Number of pages12
JournalCancer Research
Volume76
Issue number22
DOIs
Publication statusPublished - Nov 15 2016

Fingerprint

trabectedin
Ewing's Sarcoma
Oncogene Proteins
irinotecan
Transcription Factors
Neoplasms
Ultraviolet Rays
Adipocytes
Heterografts
EWS-FLI fusion protein
Proteins
Therapeutics
Phenotype
Safety
Messenger RNA

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Harlow, M. L., Maloney, N., Roland, J., Guillen Navarro, M. J., Easton, M. K., Kitchen-Goosen, S. M., ... Grohar, P. J. (2016). Lurbinectedin inactivates the Ewing sarcoma oncoprotein EWS-FLI1 by redistributing it within the nucleus. Cancer Research, 76(22), 6657-6668. https://doi.org/10.1158/0008-5472.CAN-16-0568

Lurbinectedin inactivates the Ewing sarcoma oncoprotein EWS-FLI1 by redistributing it within the nucleus. / Harlow, Matt L.; Maloney, Nichole; Roland, Joseph; Guillen Navarro, Maria Jose; Easton, Matthew K.; Kitchen-Goosen, Susan M.; Boguslawski, Elissa A.; Madaj, Zachary B.; Johnson, Ben K.; Bowman, Megan J.; D'Incalci, Maurizio; Winn, Mary E.; Turner, Lisa; Hostetter, Galen; Galmarini, Carlos María; Aviles, Pablo M.; Grohar, Patrick J.

In: Cancer Research, Vol. 76, No. 22, 15.11.2016, p. 6657-6668.

Research output: Contribution to journalArticle

Harlow, ML, Maloney, N, Roland, J, Guillen Navarro, MJ, Easton, MK, Kitchen-Goosen, SM, Boguslawski, EA, Madaj, ZB, Johnson, BK, Bowman, MJ, D'Incalci, M, Winn, ME, Turner, L, Hostetter, G, Galmarini, CM, Aviles, PM & Grohar, PJ 2016, 'Lurbinectedin inactivates the Ewing sarcoma oncoprotein EWS-FLI1 by redistributing it within the nucleus', Cancer Research, vol. 76, no. 22, pp. 6657-6668. https://doi.org/10.1158/0008-5472.CAN-16-0568
Harlow ML, Maloney N, Roland J, Guillen Navarro MJ, Easton MK, Kitchen-Goosen SM et al. Lurbinectedin inactivates the Ewing sarcoma oncoprotein EWS-FLI1 by redistributing it within the nucleus. Cancer Research. 2016 Nov 15;76(22):6657-6668. https://doi.org/10.1158/0008-5472.CAN-16-0568
Harlow, Matt L. ; Maloney, Nichole ; Roland, Joseph ; Guillen Navarro, Maria Jose ; Easton, Matthew K. ; Kitchen-Goosen, Susan M. ; Boguslawski, Elissa A. ; Madaj, Zachary B. ; Johnson, Ben K. ; Bowman, Megan J. ; D'Incalci, Maurizio ; Winn, Mary E. ; Turner, Lisa ; Hostetter, Galen ; Galmarini, Carlos María ; Aviles, Pablo M. ; Grohar, Patrick J. / Lurbinectedin inactivates the Ewing sarcoma oncoprotein EWS-FLI1 by redistributing it within the nucleus. In: Cancer Research. 2016 ; Vol. 76, No. 22. pp. 6657-6668.
@article{75cfff22121948d8a428c4de601ce99d,
title = "Lurbinectedin inactivates the Ewing sarcoma oncoprotein EWS-FLI1 by redistributing it within the nucleus",
abstract = "There is a great need to develop novel approaches to target oncogenic transcription factors with small molecules. Ewing sarcoma is emblematic of this need, as it depends on the continued activity of the EWS-FLI1 transcription factor to maintain the malignant phenotype. We have previously shown that the small molecule trabectedin interferes with EWS-FLI1. Here, we report important mechanistic advances and a second-generation inhibitor to provide insight into the therapeutic targeting of EWS-FLI1. We discovered that trabectedin functionally inactivated EWS-FLI1 by redistributing the protein within the nucleus to the nucleolus. This effect was rooted in the wild-type functions of the EWSR1, compromising the N-terminal half of the chimeric oncoprotein, which is known to be similarly redistributed within the nucleus in the presence of UV light damage. A second-generation trabectedin analogue lurbinectedin (PM01183) caused the same nuclear redistribution of EWS-FLI1, leading to a loss of activity at the promoter, mRNA, and protein levels of expression. Tumor xenograft studies confirmed this effect, and it was increased in combination with irinotecan, leading to tumor regression and replacement of Ewing sarcoma cells with benign fat cells. The net result of combined lurbinectedin and irinotecan treatment was a complete reversal of EWS-FLI1 activity and elimination of established tumors in 30{\%} to 70{\%} of mice after only 11 days of therapy. Our results illustrate the preclinical safety and efficacy of a disease-specific therapy targeting the central oncogenic driver in Ewing sarcoma.",
author = "Harlow, {Matt L.} and Nichole Maloney and Joseph Roland and {Guillen Navarro}, {Maria Jose} and Easton, {Matthew K.} and Kitchen-Goosen, {Susan M.} and Boguslawski, {Elissa A.} and Madaj, {Zachary B.} and Johnson, {Ben K.} and Bowman, {Megan J.} and Maurizio D'Incalci and Winn, {Mary E.} and Lisa Turner and Galen Hostetter and Galmarini, {Carlos Mar{\'i}a} and Aviles, {Pablo M.} and Grohar, {Patrick J.}",
year = "2016",
month = "11",
day = "15",
doi = "10.1158/0008-5472.CAN-16-0568",
language = "English",
volume = "76",
pages = "6657--6668",
journal = "Journal of Cancer Research",
issn = "0008-5472",
publisher = "American Association for Cancer Research Inc.",
number = "22",

}

TY - JOUR

T1 - Lurbinectedin inactivates the Ewing sarcoma oncoprotein EWS-FLI1 by redistributing it within the nucleus

AU - Harlow, Matt L.

AU - Maloney, Nichole

AU - Roland, Joseph

AU - Guillen Navarro, Maria Jose

AU - Easton, Matthew K.

AU - Kitchen-Goosen, Susan M.

AU - Boguslawski, Elissa A.

AU - Madaj, Zachary B.

AU - Johnson, Ben K.

AU - Bowman, Megan J.

AU - D'Incalci, Maurizio

AU - Winn, Mary E.

AU - Turner, Lisa

AU - Hostetter, Galen

AU - Galmarini, Carlos María

AU - Aviles, Pablo M.

AU - Grohar, Patrick J.

PY - 2016/11/15

Y1 - 2016/11/15

N2 - There is a great need to develop novel approaches to target oncogenic transcription factors with small molecules. Ewing sarcoma is emblematic of this need, as it depends on the continued activity of the EWS-FLI1 transcription factor to maintain the malignant phenotype. We have previously shown that the small molecule trabectedin interferes with EWS-FLI1. Here, we report important mechanistic advances and a second-generation inhibitor to provide insight into the therapeutic targeting of EWS-FLI1. We discovered that trabectedin functionally inactivated EWS-FLI1 by redistributing the protein within the nucleus to the nucleolus. This effect was rooted in the wild-type functions of the EWSR1, compromising the N-terminal half of the chimeric oncoprotein, which is known to be similarly redistributed within the nucleus in the presence of UV light damage. A second-generation trabectedin analogue lurbinectedin (PM01183) caused the same nuclear redistribution of EWS-FLI1, leading to a loss of activity at the promoter, mRNA, and protein levels of expression. Tumor xenograft studies confirmed this effect, and it was increased in combination with irinotecan, leading to tumor regression and replacement of Ewing sarcoma cells with benign fat cells. The net result of combined lurbinectedin and irinotecan treatment was a complete reversal of EWS-FLI1 activity and elimination of established tumors in 30% to 70% of mice after only 11 days of therapy. Our results illustrate the preclinical safety and efficacy of a disease-specific therapy targeting the central oncogenic driver in Ewing sarcoma.

AB - There is a great need to develop novel approaches to target oncogenic transcription factors with small molecules. Ewing sarcoma is emblematic of this need, as it depends on the continued activity of the EWS-FLI1 transcription factor to maintain the malignant phenotype. We have previously shown that the small molecule trabectedin interferes with EWS-FLI1. Here, we report important mechanistic advances and a second-generation inhibitor to provide insight into the therapeutic targeting of EWS-FLI1. We discovered that trabectedin functionally inactivated EWS-FLI1 by redistributing the protein within the nucleus to the nucleolus. This effect was rooted in the wild-type functions of the EWSR1, compromising the N-terminal half of the chimeric oncoprotein, which is known to be similarly redistributed within the nucleus in the presence of UV light damage. A second-generation trabectedin analogue lurbinectedin (PM01183) caused the same nuclear redistribution of EWS-FLI1, leading to a loss of activity at the promoter, mRNA, and protein levels of expression. Tumor xenograft studies confirmed this effect, and it was increased in combination with irinotecan, leading to tumor regression and replacement of Ewing sarcoma cells with benign fat cells. The net result of combined lurbinectedin and irinotecan treatment was a complete reversal of EWS-FLI1 activity and elimination of established tumors in 30% to 70% of mice after only 11 days of therapy. Our results illustrate the preclinical safety and efficacy of a disease-specific therapy targeting the central oncogenic driver in Ewing sarcoma.

UR - http://www.scopus.com/inward/record.url?scp=84995495626&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84995495626&partnerID=8YFLogxK

U2 - 10.1158/0008-5472.CAN-16-0568

DO - 10.1158/0008-5472.CAN-16-0568

M3 - Article

AN - SCOPUS:84995495626

VL - 76

SP - 6657

EP - 6668

JO - Journal of Cancer Research

JF - Journal of Cancer Research

SN - 0008-5472

IS - 22

ER -